Biotrend Cevre Ve Stock Current Valuation
| BIOEN Stock | TRY 17.85 0.15 0.85% |
Valuation analysis of Biotrend Cevre ve helps investors to measure Biotrend Cevre's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Biotrend Cevre's price fluctuation is not too volatile at this time. Calculation of the real value of Biotrend Cevre ve is based on 3 months time horizon. Increasing Biotrend Cevre's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biotrend Cevre is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotrend Stock. However, Biotrend Cevre's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.85 | Real 14.61 | Hype 17.85 | Naive 17.7 |
The intrinsic value of Biotrend Cevre's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Biotrend Cevre's stock price.
Estimating the potential upside or downside of Biotrend Cevre ve helps investors to forecast how Biotrend stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotrend Cevre more accurately as focusing exclusively on Biotrend Cevre's fundamentals will not take into account other important factors: Biotrend Cevre ve Company Current Valuation Analysis
Biotrend Cevre's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biotrend Cevre ve has a Current Valuation of 0.0. This is 100.0% lower than that of the Utilities sector and about the same as Utilities—Renewable (which currently averages 0.0) industry. The current valuation for all Turkey stocks is 100.0% higher than that of the company.
Biotrend Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotrend Cevre's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotrend Cevre could also be used in its relative valuation, which is a method of valuing Biotrend Cevre by comparing valuation metrics of similar companies.Biotrend Cevre is currently under evaluation in current valuation category among its peers.
Biotrend Fundamentals
| Return On Equity | 0.0978 | |||
| Return On Asset | 0.0657 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.22 % | |||
| Shares Owned By Insiders | 67.23 % | |||
| Shares Owned By Institutions | 1.80 % | |||
| Price To Earning | 114.34 X | |||
| Revenue | 427.7 M | |||
| Gross Profit | 123.34 M | |||
| EBITDA | 84.88 M | |||
| Net Income | 3.79 M | |||
| Cash And Equivalents | 25.91 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 696.56 M | |||
| Debt To Equity | 2.09 % | |||
| Current Ratio | 0.77 X | |||
| Book Value Per Share | 0.98 X | |||
| Cash Flow From Operations | (326.18 M) | |||
| Earnings Per Share | 0.01 X | |||
| Target Price | 13.1 | |||
| Number Of Employees | 529 | |||
| Total Asset | 1.83 B | |||
| Net Asset | 1.83 B |
About Biotrend Cevre Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotrend Cevre ve's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotrend Cevre using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotrend Cevre ve based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Biotrend Stock
Biotrend Cevre financial ratios help investors to determine whether Biotrend Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotrend with respect to the benefits of owning Biotrend Cevre security.